Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG.

Trial Profile

Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Melanoma vaccine (Primary) ; BCG
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Apr 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned end date changed from Apr 2010 to Mar 2009 as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top